Pediatric low-grade gliomas: How modern biology reshapes the clinical field

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1845, Issue 2, 2014, Pages 294-307

  Bergthold, Guillaume ^a   Bandopadhayay, Pratiti ^a,d   Bi, Wenya Linda ^a   Ramkissoon, Lori ^a,c   Stiles, Charles ^a   Segal, Rosalind A ^a,e   Beroukhim, Rameen ^a   Ligon, Keith L ^a,c   Grill, Jacques ^b   Kieran, Mark W ^a,d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

BRAF; Genetics; Low grade glioma; Pediatric

Indexed keywords

ALKYLATING AGENT; B RAF KINASE; BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; FLUOROURACIL; IDARUBICIN; IFOSFAMIDE; IPROPLATIN; LOMUSTINE; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; NEUROFIBROMIN; OXALIPLATIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROCARBAZINE; PROTEIN TYROSINE KINASE; TAMOXIFEN; TEMOZOLOMIDE; TIOGUANINE; TOPOTECAN; TRANSCRIPTION FACTOR; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ARTICLE; B RAF GENE; BRAIN SURGERY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CHILD; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EPIGENETICS; GENE DUPLICATION; GENE FUSION; GENETIC ANALYSIS; GENETIC PREDISPOSITION; GLIOMA; HISTOPATHOLOGY; HISTORY OF MEDICINE; HUMAN; MAPK GENE; MICROSCOPY; NEUROFIBROMIN 1 GENE; ONCOGENE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PI3K GENE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RTK GENE; SIGNAL TRANSDUCTION; SURVIVAL RATE; SURVIVAL TIME; TRANSCRIPTION FACTOR GENE; TREATMENT PLANNING;

BRAF; GENETICS; LOW-GRADE GLIOMA; PEDIATRIC;

APOPTOSIS; BRAIN NEOPLASMS; CELL SURVIVAL; EPIGENESIS, GENETIC; GLIOMA; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM GRADING; PEDIATRICS; PROGNOSIS;

EID: 84896260465     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2014.02.004     Document Type: Article

References (266)

1. Rickert C.H., Paulus W. Epidemiology of central nervous system tumors in childhood and adolescence based on the new WHO classification. Childs Nerv. Syst. 2001, 17:503-511.
2. Orkin S.H., FD, Look T.A., Lux S., Ginsburg D., Nathan D. Oncology of Infancy and Childhood 2009, Elseviers, Philadelphia.
3. Louis D.N., Ohgaki H., Wiestler O.D., et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007, 114:97-109.
4. Gajjar A.S.R., Heideman R., Jenkins J.J., Walter A., Li Y., Langston J.W., Muhlbauer M., Boyett J.M., Kun L.E. Low-grade astrocytoma: a decade of experience at St. Jude Children's Research Hospital. J. Clin. Oncol. 1997, 15:2792-2799.
5. Qaddoumi I.S.I., Broniscer A. Pediatric low-grade gliomas and the need for new options for therapy: why and how?. Cancer Biol. Ther. 2009, 8:4-10.
6. Dolecek T.A., Propp J.M., Stroup N.E., Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro. Oncol. 2012, 14(Suppl. 5):v1-v49.
7. Machen S.K., Prayson R.A. Cyclin D1 and MIB-1 immunohistochemistry in pilocytic astrocytomas: a study of 48 cases. Hum. Pathol. 1998, 29:1511-1516.
8. Prayson R.A., Khajavi K., Comair Y.G. Cortical architectural abnormalities and MIB1 immunoreactivity in gangliogliomas: a study of 60 patients with intracranial tumors. J. Neuropathol. Exp. Neurol. 1995, 54:513-520.
9. Prayson R.A., Morris H.H., Estes M.L., Comair Y.G. Dysembryoplastic neuroepithelial tumor: a clinicopathologic and immunohistochemical study of 11 tumors including MIB1 immunoreactivity. Clin. Neuropathol. 1996, 15:47-53.
10. Johannessen A.L., Torp S.H. The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas. Pathol. Oncol. Res. 2006, 12:143-147.
11. Neder L., Colli B.O., Machado H.R., Carlotti C.G., Santos A.C., Chimelli L. MIB-1 labeling index in astrocytic tumors - a clinicopathologic study. Clin. Neuropathol. 2004, 23:262-270.
12. Roessler K.B.A., Jezan H., Ba-Ssalamah A., Slavc I., Czech T., Budka H. Proliferative activity as measured by MIB-1 labeling index and long-term outcome of cerebellar juvenile pilocytic astrocytomas. J. Neurooncol. 2002, 58:141-146.
13. Kayaselcuk F., Zorludemir S., Gumurduhu D., Zeren H., Erman T. PCNA and Ki-67 in central nervous system tumors: correlation with the histological type and grade. J. Neurooncol. 2002, 57:115-121.
14. Paixao Becker A., de Oliveira R.S., Saggioro F.P., Neder L., Chimelli L.M., Machado H.R. In pursuit of prognostic factors in children with pilocytic astrocytomas. Childs Nerv. Syst. 2010, 26:19-28.
15. Bowers D.C.G.L., Kapur P., Reisch J.S., Mulne A.F., Shapiro K.N., Elterman R.D., Winick N.J., Margraf L.R. Study of the MIB-1 labeling index as a predictor of tumor progression in pilocytic astrocytomas in children and adolescents. J. Clin. Oncol. 2003, 21:2968-2973.
16. Margraf LR G.L., Butt Y., Raghunathan N., Bowers D.C. Proliferative and metabolic markers in incompletely excised pediatric pilocytic astrocytomas - an assessment of 3 new variables in predicting clinical outcome. Neuro. Oncol. 2011, 13:767-774.
17. Cummings T.J., Provenzale J.M., Hunter S.B., et al. Gliomas of the optic nerve: histological, immunohistochemical (MIB-1 and p53), and MRI analysis. Acta Neuropathol. 2000, 99:563-570.
18. Faria C., Miguens J., Antunes J.L., et al. Genetic alterations in a papillary glioneuronal tumor. J. Neurosurg. Pediatr. 2008, 1:99-102.
19. Czech T., Slavc I., Aichholzer M., et al. Proliferative activity as measured by MIB-1 labeling index and long-term outcome of visual pathway astrocytomas in children. J. Neurooncol. 1999, 42:143-150.
20. Dirven C.M.K.J., Mooij J.J., Molenaar W.M. The proliferative potential of the pilocytic astrocytoma: the relation between MIB-1 labeling and clinical and neuro-radiological follow-up. J. Neurooncol. 1998, 37:9-16.
21. Tung J.N., Tsao T.Y., Tai C.J., Yeh K.T., Cheng Y.W., Jiang M.C. Distribution of lysosome-associated membrane proteins-1 and -2, and cathepsin D in eosinophilic granular bodies: possible relationship to cyst development in pilocytic astrocytomas. J. Int. Med. Res. 2010, 38:1354-1364.
22. Berhouma M., Jemel H., Kchir N. Calcified pilocytic astrocytoma of the medulla mimicking a brainstem "stone". Pathologica 2008, 100:408-410.
23. Takei H.Y.S., Wong K.K., Mehta V., Chintagumpala M., Dauser R.C., Lau C.C., Adesina A.M. Expression of oligodendroglial differentiation markers in pilocytic astrocytomas identifies two clinical subsets and shows a significant correlation with proliferation index and progression free survival. J. Neurooncol. 2008, 86:183-190.
24. Otero J.J.R.D., Vandenberg S. OLIG2 is differentially expressed in pediatric astrocytic and in ependymal neoplasms. J. Neurooncol. 2011, 104:423-438.
25. Tanaka Y.S.A., Ishiuchi S., Nakazato Y. Diversity of glial cell components in pilocytic astrocytoma. Neuropathology Aug. 2008, 28(4):399-407. (Epub 2008 Feb 26 2008;28:399-407).
26. Ligon K.L., Huillard E., Mehta S., et al. Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron 2007, 53:503-517.
27. Gullotta F., Schindler F., Schmutzler R., Weeks-Seifert A. GFAP in brain tumor diagnosis: possibilities and limitations. Pathol. Res. Pract. 1985, 180:54-60.
28. Pfister S., Witt O. Pediatric gliomas. Recent Results Cancer Res. 2009, 171:67-81.
29. Zentner J., Wolf H.K., Ostertun B., et al. Gangliogliomas: clinical, radiological, and histopathological findings in 51 patients. J. Neurol. Neurosurg. Psychiatry 1994, 57:1497-1502.
30. Park J.Y., Suh Y.L., Han J. Dysembryoplastic neuroepithelial tumor. Features distinguishing it from oligodendroglioma on cytologic squash preparations. Acta Cytol. 2003, 47:624-629.
31. Lellouch-Tubiana A., Boddaert N., Bourgeois M., et al. Angiocentric neuroepithelial tumor (ANET): a new epilepsy-related clinicopathological entity with distinctive MRI. Brain Pathol. 2005, 15:281-286.
32. Buccoliero A.M., Castiglione F., Degl'innocenti D.R., et al. Angiocentric glioma: clinical, morphological, immunohistochemical and molecular features in three pediatric cases. Clin. Neuropathol. 2013, 32:107-113.
33. Forbes J.A., Mobley B.C., O'Lynnger T.M., et al. Pediatric cerebellar pilomyxoid-spectrum astrocytomas. J. Neurosurg. Pediatr. 2011, 8:90-96.
34. Amatya V.J., Akazawa R., Sumimoto Y., Takeshima Y., Inai K. Clinicopathological and immunohistochemical features of three pilomyxoid astrocytomas: comparative study with 11 pilocytic astrocytomas. Pathol. Int. 2009, 59:80-85.
35. Hemmati H.D.N.I., Lazareff J.A., Masterman-Smith M., Geschwind D.H., Bronner-Fraser M., Kornblum H.I. Cancerous stem cells can arise from pediatric brain tumors. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:15178-15183.
36. CBTRUS CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2008 2012.
37. Bleyer W.A. Epidemiologic impact of children with brain tumors. Childs Nerv. Syst. 1999, 15:758-763.
38. Bauchet L., Rigau V., Mathieu-Daude H., et al. Clinical epidemiology for childhood primary central nervous system tumors. J. Neurooncol. 2009, 92:87-98.
39. Kaatsch P., Rickert C.H., Kuhl J., Schuz J., Michaelis J. Population-based epidemiologic data on brain tumors in German children. Cancer 2001, 92:3155-3164.
40. Radner H., Blumcke I., Reifenberger G., Wiestler O.D. The new WHO classification of tumors of the nervous system 2000. Pathology and genetics. Pathology 2002, 23:260-283.
41. Kohler B.A., Ward E., McCarthy B.J., et al. Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J. Natl. Cancer Inst. 2011, 103:714-736.
42. Gjerris F., Agerlin N., Borgesen S.E., et al. Epidemiology and prognosis in children treated for intracranial tumours in Denmark 1960-1984. Childs Nerv. Syst. 1998, 14:302-311.
43. Pinho R.S., Andreoni S., Silva N.S., et al. Pediatric central nervous system tumors: a single-center experience from 1989 to 2009. J. Pediatr. Hematol. Oncol. 2011, 33:605-609.
44. Duffau H., Capelle L. Preferential brain locations of low-grade gliomas. Cancer 2004, 100:2622-2626.
45. Sievert A.J., Fisher M.J. Pediatric low-grade gliomas. J. Child Neurol. 2009, 24:1397-1408.
46. Freeman C.R., Farmer J.P., Montes J. Low-grade astrocytomas in children: evolving management strategies. Int. J. Radiat. Oncol. Biol. Phys. 1998, 41:979-987.
47. Rosemberg S., Fujiwara D. Epidemiology of pediatric tumors of the nervous system according to the WHO 2000 classification: a report of 1195 cases from a single institution. Childs Nerv. Syst. 2005, 21:940-944.
48. Peters O., Gnekow A.K., Rating D., Wolff J.E. Impact of location on outcome in children with low-grade oligodendroglioma. Pediatr. Blood Cancer 2004, 43:250-256.
49. Luyken C., Blumcke I., Fimmers R., Urbach H., Wiestler O.D., Schramm J. Supratentorial gangliogliomas: histopathologic grading and tumor recurrence in 184 patients with a median follow-up of 8years. Cancer 2004, 101:146-155.
50. Fernandez C., Figarella-Branger D., Girard N., et al. Pilocytic astrocytomas in children: prognostic factors - a retrospective study of 80 cases. Neurosurgery 2003, 53:544-553. (discussion 54-5).
51. Scheinemann K., Bartels U., Huang A., et al. Survival and functional outcome of childhood spinal cord low-grade gliomas. Clinical article. J. Neurosurg. Pediatr. 2009, 4:254-261.
52. Robertson P.L., Allen J.C., Abbott I.R., Miller D.C., Fidel J., Epstein F.J. Cervicomedullary tumors in children: a distinct subset of brainstem gliomas. Neurology 1994, 44:1798-1803.
53. Rodriguez F.J., Perry A., Gutmann D.H., et al. Gliomas in neurofibromatosis type 1: a clinicopathologic study of 100 patients. J. Neuropathol. Exp. Neurol. 2008, 67:240-249.
54. Guillamo J.S., Creange A., Kalifa C., et al. Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1): a retrospective study of 104 patients. Brain 2003, 126:152-160.
55. Korf B.R. Malignancy in neurofibromatosis type 1. Oncologist 2000, 5:477-485.
56. Hernaiz Driever P., von Hornstein S., Pietsch T., et al. Natural history and management of low-grade glioma in NF-1 children. J. Neurooncol. 2010, 100:199-207.
57. Listernick R., Louis D.N., Packer R.J., Gutmann D.H. Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann. Neurol. 1997, 41:143-149.
58. Blazo M.A., Lewis R.A., Chintagumpala M.M., Frazier M., McCluggage C., Plon S.E. Outcomes of systematic screening for optic pathway tumors in children with neurofibromatosis type 1. Am. J. Med. Genet. A 2004, 127A:224-229.
59. Al-Saleem T., Wessner L.L., Scheithauer B.W., et al. Malignant tumors of the kidney, brain, and soft tissues in children and young adults with the tuberous sclerosis complex. Cancer 1998, 83:2208-2216.
60. Hirose T., Scheithauer B.W., Lopes M.B., et al. Tuber and subependymal giant cell astrocytoma associated with tuberous sclerosis: an immunohistochemical, ultrastructural, and immunoelectron and microscopic study. Acta Neuropathol. 1995, 90:387-399.
61. van Slegtenhorst M., de Hoogt R., Hermans C., et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997, 277:805-808.
62. Bilginer B., Narin F., Oguz K.K., Uzun S., Soylemezoglu F., Akalan N. Benign cerebellar pilocytic astrocytomas in children. Turk. Neurosurg. 2011, 21:22-26.
63. Gelabert-Gonzalez M., Amo J.M., Arcos Algaba A., et al. Intracranial gangliogliomas. A review of a series of 20 patients. Neurologia 2011, 26:405-415.
64. Prayson R.A. Tumours arising in the setting of paediatric chronic epilepsy. Pathology 2010, 42:426-431.
65. Alexiou G.A., Varela M., Sfakianos G., Prodromou N. Benign lesions accompanied by intractable epilepsy in children. J. Child Neurol. 2009, 24:697-700.
66. De Rose M., Luzi M., Trignani R., et al. Cingulate epilepsy in a child with a low-grade glioma. Childs Nerv. Syst. 2009, 25:1507-1511.
67. Gaggero R., Consales A., Fazzini F., et al. Epilepsy associated with supratentorial brain tumors under 3years of life. Epilepsy Res. 2009, 87:184-189.
68. Huber J., Sovinz P., Lackner H., Mokry M., Eder H., Urban C. Diencephalic syndrome: a frequently delayed diagnosis in failure to thrive. Klin. Padiatr. 2007, 219:91-94.
69. Waga S., Shimizu T., Sakakura M. Diencephalic syndrome of emaciation (Russell's syndrome). Surg. Neurol. 1982, 17:141-146.
70. Perilongo G., Carollo C., Salviati L., et al. Diencephalic syndrome and disseminated juvenile pilocytic astrocytomas of the hypothalamic-optic chiasm region. Cancer 1997, 80:142-146.
71. Czyzyk E., Jozwiak S., Roszkowski M., Schwartz R.A. Optic pathway gliomas in children with and without neurofibromatosis 1. J. Child Neurol. 2003, 18:471-478.
72. Rondinelli P.I., Osorio C.A., Cohen M.P., Novaes P.E. Unusual dissemination patterns of low-grade astrocytomas in childhood. Arq. Neuro Psiquiatr. 2008, 66:45-49.
73. Civitello L.A., Packer R.J., Rorke L.B., Siegel K., Sutton L.N., Schut L. Leptomeningeal dissemination of low-grade gliomas in childhood. Neurology 1988, 38:562-566.
74. Perilongo G., Garre M.L., Giangaspero F. Low-grade gliomas and leptomeningeal dissemination: a poorly understood phenomenon. Childs Nerv. Syst. 2003, 19:197-203.
75. Hukin J.S.J., Cohen H., Velasquez L., Zagzag D., Allen J. Leptomeningeal dissemination at diagnosis of pediatric low-grade neuroepithelial tumors. NeuroOncol. 2003, 5:188-196.
76. Mazloom A., Hodges J.C., Teh B.S., Chintagumpala M., Paulino A.C. Outcome of patients with pilocytic astrocytoma and leptomeningeal dissemination. Int. J. Radiat. Oncol. Biol. Phys. 2012, 84:350-354.
77. von Hornstein S., Kortmann R.D., Pietsch T., et al. Impact of chemotherapy on disseminated low-grade glioma in children and adolescents: report from the HIT-LGG 1996 trial. Pediatr. Blood Cancer 2011, 56:1046-1054.
78. Porto L., Kieslich M., Franz K., et al. Spectroscopy of untreated pilocytic astrocytomas: do children and adults share some metabolic features in addition to their morphologic similarities?. Childs Nerv. Syst. 2010, 26:801-806.
79. Strong J.A.H.H.J., Brown M.T., Debatin J.F., Friedman H.S., Oakes W.J., Tien R. Pilocytic astrocytoma: correlation between the initial imaging features and clinical aggressiveness. AJR Am. J. Roentgenol. 1993, 161:369-372.
80. Lee Y.Y., Van Tassel P., Bruner J.M., Moser R.P., Share J.C. Juvenile pilocytic astrocytomas: CT and MR characteristics. AJR Am. J. Roentgenol. 1989, 152:1263-1270.
81. Seo H.S., Kim J.H., Lee D.H., et al. Nonenhancing intramedullary astrocytomas and other MR imaging features: a retrospective study and systematic review. AJNR Am. J. Neuroradiol. 2010, 31:498-503.
82. Komotar R.J., Zacharia B.E., Sughrue M.E., et al. Magnetic resonance imaging characteristics of pilomyxoid astrocytoma. Neurol. Res. 2008, 30:945-951.
83. Chang S.C., Lai P.H., Chen W.L., et al. Diffusion-weighted MRI features of brain abscess and cystic or necrotic brain tumors: comparison with conventional MRI. Clin. Imaging 2002, 26:227-236.
84. Fisher P.G., Tihan T., Goldthwaite P.T., et al. Outcome analysis of childhood low-grade astrocytomas. Pediatr. Blood Cancer 2008, 51:245-250.
85. Perilongo G., Moras P., Carollo C., et al. Spontaneous partial regression of low-grade glioma in children with neurofibromatosis-1: a real possibility. J. Child Neurol. 1999, 14:352-356.
86. Rozen W.M.J.S., Lo P.A. Spontaneous regression of low-grade gliomas in pediatric patients without neurofibromatosis. Pediatr. Neurosurg. 2008, 44:324-328.
87. Gunny R.S., Hayward R.D., Phipps K.P., Harding B.N., Saunders D.E. Spontaneous regression of residual low-grade cerebellar pilocytic astrocytomas in children. Pediatr. Radiol. 2005, 35:1086-1091.
88. Schmandt S.M., Packer R.J., Vezina L.G., Jane J. Spontaneous regression of low-grade astrocytomas in childhood. Pediatr. Neurosurg. 2000, 32:132-136.
89. Kernan J.C., Horgan M.A., Piatt J.H., D'Agostino A. Spontaneous involution of a diencephalic astrocytoma. Pediatr. Neurosurg. 1998, 29:149-153.
90. Kornreich L., Blaser S., Schwarz M., et al. Optic pathway glioma: correlation of imaging findings with the presence of neurofibromatosis. AJNR Am. J. Neuroradiol. 2001, 22:1963-1969.
91. Pollack I.F., Shultz B., Mulvihill J.J. The management of brainstem gliomas in patients with neurofibromatosis 1. Neurology 1996, 46:1652-1660.
92. Milstein J.M., Geyer J.R., Berger M.S., Bleyer W.A. Favorable prognosis for brainstem gliomas in neurofibromatosis. J. Neurooncol. 1989, 7:367-371.
93. Stokland T., Liu J.F., Ironside J.W., et al. A multivariate analysis of factors determining tumor progression in childhood low-grade glioma: a population-based cohort study (CCLG CNS9702). Neuro Oncol. 2010, 12:1257-1268.
94. Pollack I.F., Claassen D., al-Shboul Q., Janosky J.E., Deutsch M. Low-grade gliomas of the cerebral hemispheres in children: an analysis of 71 cases. J. Neurosurg. 1995, 82:536-547.
95. Fouladi M., Hunt D.L., Pollack I.F., et al. Outcome of children with centrally reviewed low-grade gliomas treated with chemotherapy with or without radiotherapy on Children's Cancer Group High-grade Glioma Study CCG-945. Cancer 2003, 98:1243-1252.
96. Smoots D.W., Geyer J.R., Lieberman D.M., Berger M.S. Predicting disease progression in childhood cerebellar astrocytoma. Childs Nerv. Syst. 1998, 14:636-648.
97. El Khashab M.G.L., Margraf L., Koral K., Nejat F., Swift D., Weprin B., Bowers D.C. Predictors of tumor progression among children with gangliogliomas. Clinical article. J. Neurosurg. Pediatr. 2009, 3:461-466.
98. Bowers D.C., Mulne A.F., Weprin B., Bruce D.A., Shapiro K., Margraf L.R. Prognostic factors in children and adolescents with low-grade oligodendrogliomas. Pediatr. Neurosurg. 2002, 37:57-63.
99. Opocher E., Kremer L.C., Da Dalt L., et al. Prognostic factors for progression of childhood optic pathway glioma: a systematic review. Eur. J. Cancer 2006, 42:1807-1816.
100. Ater J.L., Zhou T., Holmes E., et al. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group. J. Clin. Oncol. 2012, 30:2641-2647.
101. Parsa C.F.G.S. Juvenile pilocytic astrocytomas do not undergo spontaneous malignant transformation: grounds for designation as hamartomas. Br. J. Ophthalmol. 2008, 92:40-46.
102. Zoeller G.K., Brathwaite C.D., Sandberg D.I. Malignant transformation of an optic pathway glioma without prior radiation therapy. J. Neurosurg. Pediatr. 2010, 5:507-510.
103. Unal E., Koksal Y., Cimen O., Paksoy Y., Tavli L. Malignant glioblastomatous transformation of a low-grade glioma in a child. Childs Nerv. Syst. 2008, 24:1385-1389.
104. Qaddoumi I., Sultan I., Gajjar A. Outcome and prognostic features in pediatric gliomas: a review of 6212 cases from the Surveillance, Epidemiology, and End Results database. Cancer 2009, 115:5761-5770.
105. Wisoff J.H., Sanford R.A., Heier L.A., et al. Primary neurosurgery for pediatric low-grade gliomas: a prospective multi-institutional study from the Children's Oncology Group. Neurosurgery 2011, 68:1548-1554. (discussion 54-5).
106. Benesch M.E.H., Sovinz P., Raith J., Lackner H., Moser A., Urban C. Residual or recurrent cerebellar low-grade glioma in children after tumor resection: is re-treatment needed? A single center experience from 1983 to 2003. Pediatr. Neurosurg. 2006, 42:159-164.
107. Laws E.R., Taylor W.F., Clifton M.B., Okazaki H. Neurosurgical management of low-grade astrocytoma of the cerebral hemispheres. J. Neurosurg. 1984, 61:665-673.
108. Uliel-Sibony S., Kramer U., Fried I., Fattal-Valevski A., Constantini S. Pediatric temporal low-grade glial tumors: epilepsy outcome following resection in 48 children. Childs Nerv. Syst. 2011, 27:1413-1418.
109. Teo C., Siu T.L. Radical resection of focal brainstem gliomas: is it worth doing?. Childs Nerv. Syst. 2008, 24:1307-1314.
110. Ramina R.C.N.M., Fernandes Y.B., Borges G., Honorato D.C., Arruda W.O. Intrinsic tectal low grade astrocytomas: is surgical removal an alternative treatment? Long-term outcome of eight cases. Arq. Neuro Psiquiatr. 2005, 63:40-45.
111. Moghrabi A., Friedman H.S., Burger P.C., Tien R., Oakes W.J. Carboplatin treatment of progressive optic pathway gliomas to delay radiotherapy. J. Neurosurg. 1993, 79:223-227.
112. Aquino V.M., Fort D.W., Kamen B.A. Carboplatin for the treatment of children with newly diagnosed optic chiasm gliomas: a phase II study. J. Neurooncol. 1999, 41:255-259.
113. Gururangan S., Cavazos C.M., Ashley D., et al. Phase II study of carboplatin in children with progressive low-grade gliomas. J. Clin. Oncol. 2002, 20:2951-2958.
114. Hsu T.R., Wong T.T., Chang F.C., et al. Responsiveness of progressive optic pathway tumors to cisplatin-based chemotherapy in children. Childs Nerv. Syst. 2008, 24:1457-1461.
115. Beaty O., Berg S., Blaney S., et al. A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group study. Pediatr. Blood Cancer 2010, 55:440-445.
116. Friedman H.S., Krischer J.P., Burger P., et al. Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study. J. Clin. Oncol. 1992, 10:249-256.
117. Packer R.J., Lange B., Ater J., et al. Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J. Clin. Oncol. 1993, 11:850-856.
118. Packer R.J., Ater J., Allen J., et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J. Neurosurg. 1997, 86:747-754.
119. Demaerel P., de Ruyter N., Casteels I., Renard M., Uyttebroeck A., van Gool S. Visual pathway glioma in children treated with chemotherapy. Eur. J. Paediatr. Neurol. 2002, 6:207-212.
120. Gnekow A.K.K.R., Pietsch T., Emser A. Low grade chiasmatic-hypothalamic glioma-carboplatin and vincristine chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy - report from the multicenter treatment study for children and adolescents with a low grade glioma - HIT-LGG 1996 - of the Society of Pediatric Oncology and Hematology (GPOH). Klin. Padiatr. 2004, 216:331-342.
121. Ronghe M., Hargrave D., Bartels U., et al. Vincristine and carboplatin chemotherapy for unresectable and/or recurrent low-grade astrocytoma of the brainstem. Pediatr. Blood Cancer 2010, 55:471-477.
122. Sawamura Y., Kamoshima Y., Kato T., Tajima T., Tsubaki J. Chemotherapy with cisplatin and vincristine for optic pathway/hypothalamic astrocytoma in young children. Jpn. J. Clin. Oncol. 2009, 39:277-283.
123. Massimino M., Spreafico F., Cefalo G., et al. High response rate to cisplatin/etoposide regimen in childhood low-grade glioma. J. Clin. Oncol. 2002, 20:4209-4216.
124. Massimino M., Spreafico F., Riva D., et al. A lower-dose, lower-toxicity cisplatin-etoposide regimen for childhood progressive low-grade glioma. J. Neurooncol. 2010, 100:65-71.
125. Castello M.A.S.A., Padula A., Varrasso G., Properzi E., Trasimeni G., Operamolla P., Gualdi G.F., Clerico A. Does chemotherapy have a role in low-grade astrocytoma management? A report of 13 cases. Med. Pediatr. Oncol. 1995, 25:102-108.
126. Yu D.Y., Dahl G.V., Shames R.S., Fisher P.G. Weekly dosing of carboplatin increases risk of allergy in children. J. Pediatr. Hematol. Oncol. 2001, 23:349-352.
127. Lazzareschi I., Ruggiero A., Riccardi R., Attina G., Colosimo C., Lasorella A. Hypersensitivity reactions to carboplatin in children. J. Neurooncol. 2002, 58:33-37.
128. Lafay-Cousin L., Sung L., Carret A.S., et al. Carboplatin hypersensitivity reaction in pediatric patients with low-grade glioma: a Canadian Pediatric Brain Tumor Consortium experience. Cancer 2008, 112:892-899.
129. Lancaster D.L., Hoddes J.A., Michalski A. Tolerance of nitrosurea-based multiagent chemotherapy regime for low-grade pediatric gliomas. J. Neurooncol. 2003, 63:289-294.
130. Prados M.D., Edwards M.S., Rabbitt J., Lamborn K., Davis R.L., Levin V.A. Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen. J. Neurooncol. 1997, 32:235-241.
131. Mishra K.K., Squire S., Lamborn K., et al. Phase II TPDCV protocol for pediatric low-grade hypothalamic/chiasmatic gliomas: 15-year update. J. Neurooncol. 2010, 100:121-127.
132. Walter A.W., Gajjar A., Reardon D.A., et al. Tamoxifen and carboplatin for children with low-grade gliomas: a pilot study at St. Jude Children's Research Hospital. J. Pediatr. Hematol. Oncol. 2000, 22:247-251.
133. Jakacki R.I., Bouffet E., Adamson P.C., et al. A phase 1 study of vinblastine in combination with carboplatin for children with low-grade gliomas: a Children's Oncology Group phase 1 consortium study. Neuro. Oncol. 2011, 13:910-915.
134. Laithier V., Grill J., Le Deley M.C., et al. Progression-free survival in children with optic pathway tumors: dependence on age and the quality of the response to chemotherapy - results of the first French prospective study for the French Society of Pediatric Oncology. J. Clin. Oncol. 2003, 21:4572-4578.
135. Bruggers C.S., Greene D. A phase 2 feasibility study of sequential, dose intensive chemotherapy to treat progressive low-grade gliomas in children. J. Pediatr. Hematol. Oncol. 2007, 29:602-607.
136. Lee M.J., Ra Y.S., Park J.B., et al. Effectiveness of novel combination chemotherapy, consisting of 5-fluorouracil, vincristine, cyclophosphamide and etoposide, in the treatment of low-grade gliomas in children. J. Neurooncol. 2006, 80:277-284.
137. Scheinemann K., Bartels U., Tsangaris E., et al. Feasibility and efficacy of repeated chemotherapy for progressive pediatric low-grade gliomas. Pediatr. Blood Cancer Jul 15 2011, 57(1):84-88.
138. Nicholson H.S., Kretschmar C.S., Krailo M., et al. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer 2007, 110:1542-1550.
139. Gururangan S., Fisher M.J., Allen J.C., et al. Temozolomide in children with progressive low-grade glioma. Neuro. Oncol. 2007, 9:161-168.
140. Khaw S.L., Coleman L.T., Downie P.A., Heath J.A., Ashley D.M. Temozolomide in pediatric low-grade glioma. Pediatr. Blood Cancer 2007, 49:808-811.
141. Bartels U.B.S., Carret A.S., Crooks B., Hukin J., Johnston D., Silva M., Strother D., Wilson B., Zelcer S., Eisenstat D., Sung L., Bouffet E. The use and effectiveness of temozolomide in children with central nervous system tumours: a survey from the Canadian Paediatric Brain Tumour Consortium. Curr. Oncol. 2011, 18:e19-e24.
142. Lafay-Cousin L., Holm S., Qaddoumi I., et al. Weekly vinblastine in pediatric low-grade glioma patients with carboplatin allergic reaction. Cancer 2005, 103:2636-2642.
143. Bouffet E., Jakacki R., Goldman S., et al. Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. J. Clin. Oncol. 2012, 30:1358-1363.
144. Singh G., Wei X.C., Hader W., Chan J.A., Bouffet E., Lafay-Cousin L. Sustained response to weekly vinblastine in 2 children with pilomyxoid astrocytoma associated with diencephalic syndrome. J. Pediatr. Hematol. Oncol. Mar 2013, 35(2):e53-e56.
145. Kadota R.P., Kun L.E., Langston J.W., et al. Cyclophosphamide for the treatment of progressive low-grade astrocytoma: a Pediatric Oncology Group phase II study. J. Pediatr. Hematol. Oncol. 1999, 21:198-202.
146. Pons M.A., Finlay J.L., Walker R.W., Puccetti D., Packer R.J., McElwain M. Chemotherapy with vincristine (VCR) and etoposide (VP-16) in children with low-grade astrocytoma. J. Neurooncol. 1992, 14:151-158.
147. Sumer T., Freeman A.I., Cohen M., Bremer A.M., Thomas P.R., Sinks L.F. Chemotherapy in recurrent noncystic low-grade astrocytomas of the cerebrum in children. J. Surg. Oncol. 1978, 10:45-54.
148. Rosenstock J.G., Evans A.E., Schut L. Response to vincristine of recurrent brain tumors in children. J. Neurosurg. 1976, 45:135-140.
149. Sutton L.N., Molloy P.T., Sernyak H., et al. Long-term outcome of hypothalamic/chiasmatic astrocytomas in children treated with conservative surgery. J. Neurosurg. 1995, 83:583-589.
150. Heideman R.L., Douglass E.C., Langston J.A., et al. A phase II study of every other day high-dose ifosfamide in pediatric brain tumors: a Pediatric Oncology Group study. J. Neurooncol. 1995, 25:77-84.
151. McCowage G., Tien R., McLendon R., et al. Successful treatment of childhood pilocytic astrocytomas metastatic to the leptomeninges with high-dose cyclophosphamide. Med. Pediatr. Oncol. 1996, 27:32-39.
152. Disabato J.A.H.M., Strain J.D., Fleitz J.M., Foreman N.K. Successful use of intracavitary bleomycin for low-grade astrocytoma tumor cyst. Pediatr. Neurosurg. 1999, 31:246-250.
153. Blaney S.M., Phillips P.C., Packer R.J., et al. Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer 1996, 78:527-531.
154. Dreyer Z.E., Kadota R.P., Stewart C.F., et al. Phase 2 study of idarubicin in pediatric brain tumors: Pediatric Oncology Group study POG 9237. Neuro. Oncol. 2003, 5:261-267.
155. Warren K.E., Goldman S., Pollack I.F., et al. Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium Study PBTC-018. J. Clin. Oncol. 2011, 29:324-329.
156. Packer R.J., Jakacki R., Horn M., et al. Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. Pediatr. Blood Cancer 2009, 52:791-795.
157. Couec M.L., Andre N., Thebaud E., et al. Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: toxicity and efficacy trends. Pediatr. Blood Cancer 2012, 59:34-38.
158. Gururangan S., Fangusaro J., Poussaint T.Y., et al. Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas - a Pediatric Brain Tumor Consortium study. Neuro. Oncol. Jan 2014, 16(2):310-317.
159. Grill J., Couanet D., Cappelli C., et al. Radiation-induced cerebral vasculopathy in children with neurofibromatosis and optic pathway glioma. Ann. Neurol. 1999, 45:393-396.
160. Armstrong G.T., Conklin H.M., Huang S., et al. Survival and long-term health and cognitive outcomes after low-grade glioma. Neuro. Oncol. 2011, 13:223-234.
161. Dirks P.B., Jay V., Becker L.E., et al. Development of anaplastic changes in low-grade astrocytomas of childhood. Neurosurgery 1994, 34:68-78.
162. Merchant T.E., Kun L.E., Wu S., Xiong X., Sanford R.A., Boop F.A. Phase II trial of conformal radiation therapy for pediatric low-grade glioma. J. Clin. Oncol. 2009, 27:3598-3604.
163. Merchant T.E., Conklin H.M., Wu S., Lustig R.H., Xiong X. Late effects of conformal radiation therapy for pediatric patients with low-grade glioma: prospective evaluation of cognitive, endocrine, and hearing deficits. J. Clin. Oncol. 2009, 27:3691-3697.
164. Nishihori T., Shirato H., Aoyama H., et al. Three-dimensional conformal radiotherapy for astrocytic tumors involving the eloquent area in children and young adults. J. Neurooncol. 2002, 60:177-183.
165. Saran F.H., Baumert B.G., Khoo V.S., et al. Stereotactically guided conformal radiotherapy for progressive low-grade gliomas of childhood. Int. J. Radiat. Oncol. Biol. Phys. 2002, 53:43-51.
166. Marcus K.J., Goumnerova L., Billett A.L., et al. Stereotactic radiotherapy for localized low-grade gliomas in children: final results of a prospective trial. Int. J. Radiat. Oncol. Biol. Phys. 2005, 61:374-379.
167. Roberge D.S.L., Olivier A., Leblanc R., Podgorsak E. Hypofractionated stereotactic radiotherapy for low grade glioma at McGill University: long-term follow-up. Technol. Cancer Res. Treat. 2006, 5:1-8.
168. Henderson M.A., Fakiris A.J., Timmerman R.D., Worth R.M., Lo S.S., Witt T.C. Gamma knife stereotactic radiosurgery for low-grade astrocytomas. Stereotact. Funct. Neurosurg. 2009, 87:161-167.
169. Wang L.W., Shiau C.Y., Chung W.Y., et al. Gamma Knife surgery for low-grade astrocytomas: evaluation of long-term outcome based on a 10-year experience. J. Neurosurg. 2006, 105(Suppl.):127-132.
170. Kida Y., Kobayashi T., Mori Y. Gamma knife radiosurgery for low-grade astrocytomas: results of long-term follow up. J. Neurosurg. 2000, 93(Suppl. 3):42-46.
171. Hug E.B., Muenter M.W., Archambeau J.O., et al. Conformal proton radiation therapy for pediatric low-grade astrocytomas. Strahlenther. Onkol. 2002, 178:10-17.
172. Kuhlthau K.A., Pulsifer M.B., Yeap B.Y., et al. Prospective study of health-related quality of life for children with brain tumors treated with proton radiotherapy. J. Clin. Oncol. 2012, 30:2079-2086.
173. Meyerson M., Gabriel S., Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat. Rev. Genet. 2010, 11:685-696.
174. Bigner S.H., McLendon R.E., Fuchs H., McKeever P.E., Friedman H.S. Chromosomal characteristics of childhood brain tumors. Cancer Genet. Cytogenet. 1997, 97:125-134.
175. Rey J.A., Bello M.J., de Campos J.M., Kusak M.E., Moreno S. Chromosomal composition of a series of 22 human low-grade gliomas. Cancer Genet. Cytogenet. 1987, 29:223-237.
176. Bhattacharjee M.B., Armstrong D.D., Vogel H., Cooley L.D. Cytogenetic analysis of 120 primary pediatric brain tumors and literature review. Cancer Genet. Cytogenet. 1997, 97:39-53.
177. Griffin C.A., Long P.P., Carson B.S., Brem H. Chromosome abnormalities in low-grade central nervous system tumors. Cancer Genet. Cytogenet. 1992, 60:67-73.
178. Neumann E.K.D., Norman M.G., Steinbok P., Cochrane D.D., Goddard K. Cytogenetic analysis of 109 pediatric central nervous system tumors. Cancer Genet. Cytogenet. 1993, 71:40-49.
179. White F.V., Anthony D.C., Yunis E.J., Tarbell N.J., Scott R.M., Schofield D.E. Nonrandom chromosomal gains in pilocytic astrocytomas of childhood. Hum. Pathol. 1995, 26:979-986.
180. Zattara-Cannoni H.G.D., Lena G., Dufour H., Choux M., Grisoli F., Vagner-Capodano A.M. Are juvenile pilocytic astrocytomas benign tumors? A cytogenetic study in 24 cases. Cancer Genet. Cytogenet. 1998, 104:157-160.
181. Karnes P.S., Tran T.N., Cui M.Y., et al. Cytogenetic analysis of 39 pediatric central nervous system tumors. Cancer Genet. Cytogenet. 1992, 59:12-19.
182. Neumann E., Kalousek D.K., Norman M.G., Steinbok P., Cochrane D.D., Goddard K. Cytogenetic analysis of 109 pediatric central nervous system tumors. Cancer Genet. Cytogenet. 1993, 71:40-49.
183. Willert J.R., Daneshvar L., Sheffield V.C., Cogen P.H. Deletion of chromosome arm 17p DNA sequences in pediatric high-grade and juvenile pilocytic astrocytomas. Genes Chromosomes Cancer 1995, 12:165-172.
184. Sawyer J.R., Thomas J.R., Teo C. Low-grade astrocytoma with a complex four-breakpoint inversion of chromosome 8 as the sole cytogenetic aberration. Cancer Genet. Cytogenet. 1995, 83:168-171.
185. Orr L.C., Fleitz J., McGavran L., Wyatt-Ashmead J., Handler M., Foreman N.K. Cytogenetics in pediatric low-grade astrocytomas. Med. Pediatr. Oncol. 2002, 38:173-177.
186. Makar A.B., McMartin K.E., Palese M., Tephly T.R. Formate assay in body fluids: application in methanol poisoning. Biochem. Med. 1975, 13:117-126.
187. Smith J.S.P.A., Borell T.J., Lee H.K., O'Fallon J., Hosek S.M., Kimmel D., Yates A., Burger P.C., Scheithauer B.W., Jenkins R.B. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J. Clin. Oncol. 2000, 18:636-645.
188. Nakamura M., Shimada K., Ishida E., et al. Molecular pathogenesis of pediatric astrocytic tumors. Neuro. Oncol. 2007, 9:113-123.
189. Suri V.J.P., Agarwal S., Pathak P., Sharma M.C., Sharma V., Shukla S., Somasundaram K., Mahapatra A.K., Kale S.S., Sarkar C. Molecular profile of oligodendrogliomas in young patients. Neuro. Oncol. 2011, 13:1099-1106.
190. Kreiger P.A., Okada Y., Simon S., Rorke L.B., Louis D.N., Golden J.A. Losses of chromosomes 1p and 19q are rare in pediatric oligodendrogliomas. Acta Neuropathol. 2005, 109:387-392.
191. Huang H., Okamoto Y., Yokoo H., et al. Gene expression profiling and subgroup identification of oligodendrogliomas. Oncogene 2004, 23:6012-6022.
192. Pollack I.F., Finkelstein S.D., Burnham J., et al. Age and TP53 mutation frequency in childhood malignant gliomas: results in a multi-institutional cohort. Cancer Res. 2001, 61:7404-7407.
193. Litofsky N.S., Hinton D., Raffel C. The lack of a role for p53 in astrocytomas in pediatric patients. Neurosurgery 1994, 34:967-972. (discussion 72-3).
194. MacConaill L.E., Campbell C.D., Kehoe S.M., et al. Profiling critical cancer gene mutations in clinical tumor samples. PLoS ONE 2009, 4:e7887.
195. Patt S., Gries H., Giraldo M., et al. p53 gene mutations in human astrocytic brain tumors including pilocytic astrocytomas. Hum. Pathol. 1996, 27:586-589.
196. Paulus W., Lisle D.K., Tonn J.C., et al. Molecular genetic alterations in pleomorphic xanthoastrocytoma. Acta Neuropathol. 1996, 91:293-297.
197. Yan H., Parsons D.W., Jin G., et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 2009, 360:765-773.
198. Miwa T.H.Y., Sasaki H., Ezaki T., Yoshida K., Kawase T. Single-copy gain of chromosome 1q is a negative prognostic marker in pediatric nonependymal, nonpilocytic gliomas. Neurosurgery 2011, 68:206-212.
199. Padovani L., Colin C., Fernandez C., et al. Search for distinctive markers in DNT and cortical grade II glioma in children: same clinicopathological and molecular entities?. Curr. Top. Med. Chem. 2012, 12:1683-1692.
200. Ballester R., Marchuk D., Boguski M., et al. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell 1990, 63:851-859.
201. Yunoue S., Tokuo H., Fukunaga K., et al. Neurofibromatosis type I tumor suppressor neurofibromin regulates neuronal differentiation via its GTPase-activating protein function toward Ras. J. Biol. Chem. 2003, 278:26958-26969.
202. Deshmukh H., Yeh T.H., Yu J., et al. High-resolution, dual-platform aCGH analysis reveals frequent HIPK2 amplification and increased expression in pilocytic astrocytomas. Oncogene 2008, 27:4745-4751.
203. Hoischen A., Ehrler M., Fassunke J., et al. Comprehensive characterization of genomic aberrations in gangliogliomas by CGH, array-based CGH and interphase FISH. Brain Pathol. 2008, 18:326-337.
204. Jacob K.A.S., Sollier C., Faury D., Sader E., Montpetit A., Serre D., Hauser P., Garami M., Bognar L., Hanzely Z., Montes J.L., Atkinson J., Farmer J.P., Bouffet E., Hawkins C., Tabori U., Jabado N. Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours. Br. J. Cancer 2009, 101:722-733.
205. Pfister S., Janzarik W.G., Remke M., et al. BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J. Clin. Invest. 2008, 118:1739-1749.
206. Sievert A.J., Jackson E.M., Gai X., et al. Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene. Brain Pathol. 2009, 19:449-458.
207. Forshew T., Tatevossian R.G., Lawson A.R., et al. Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. J. Pathol. 2009, 218:172-181.
208. Lin A., Rodriguez F.J., Karajannis M.A., et al. BRAF alterations in primary glial and glioneuronal neoplasms of the central nervous system with identification of 2 novel KIAA1549:BRAF fusion variants. J. Neuropathol. Exp. Neurol. 2012, 71:66-72.
209. Jones D.T.K.S., Liu L., Pearson D.M., Ichimura K., Collins V.P. Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene 2009, 28:2119-2123.
210. Cin H., Meyer C., Herr R., et al. Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta Neuropathol. 2011, 121:763-774.
211. Zhang J., Wu G., Miller C.P., et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat. Genet. 2013, 45:602-612.
212. Jones D.T., Hutter B., Jager N., et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat. Genet. 2013, 45:927-932.
213. Lawson A.R., Hindley G.F., Forshew T., et al. RAF gene fusion breakpoints in pediatric brain tumors are characterized by significant enrichment of sequence microhomology. Genome Res. 2011, 21:505-514.
214. Jones D.T., Kocialkowski S., Liu L., et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 2008, 68:8673-8677.
215. Maldonado J.L., Fridlyand J., Patel H., et al. Determinants of BRAF mutations in primary melanomas. J. Natl. Cancer Inst. 2003, 95:1878-1890.
216. Li W.Q., Kawakami K., Ruszkiewicz A., Bennett G., Moore J., Iacopetta B. BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. Mol. Cancer 2006, 5:2.
217. Takahashi Y., Mori J., Kami M. BRAF mutations in hairy-cell leukemia. N. Engl. J. Med. 2011, 365:960-961. (author reply 1-2).
218. Yeo Y.H., Byrne N.P., Counelis G.J., Perry A. Adult with cerebellar anaplastic pilocytic astrocytoma associated with BRAF V600E mutation and p16 loss. Clin. Neuropathol. 2013, 32:159-164.
219. Lawrence M.S., Stojanov P., Mermel C.H., et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature Jan 23 2014, 505(7484):495-501.
220. Schiffman J.D.H.J., VandenBerg S.R., Flaherty P., Polley M.Y., Yu M., Fisher P.G., Rowitch D.H., Ford J.M., Berger M.S., Ji H., Gutmann D.H., James C.D. Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res. 2010, 70:512-519.
221. Dougherty M.J., Santi M., Brose M.S., et al. Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro. Oncol. 2010, 12:621-630.
222. Dias-Santagata D., Lam Q., Vernovsky K., et al. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS ONE 2011, 6:e17948.
223. Schindler G., Capper D., Meyer J., et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 2011, 121:397-405.
224. Horbinski Craig, MNN, Hagenkord Ronald L., Hamilton Pollack aIF. Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas. Neuro. Oncol. Jun 2012, 14(6):777-789.
225. Raabe E.H.L.K., Kim J.M., Meeker A., Mao X.G., Nikkhah G., Maciaczyk J., Kahlert U., Jain D., Bar E., Cohen K.J., Eberhart C.G. BRAF activation induces transformation and then senescence in human neural stem cells: a pilocytic astrocytoma model. Clin. Cancer Res. 2011, 17:3590-3599.
226. Sharma M.K., Zehnbauer B.A., Watson M.A., Gutmann D.H. RAS pathway activation and an oncogenic RAS mutation in sporadic pilocytic astrocytoma. Neurology 2005, 65:1335-1336.
227. Janzarik W.G.K.C., Loges N.T., Olbrich H., Klein C., Schäfer T., Scheurlen W., Roggendorf W., Weiller C., Niemeyer C., Korinthenberg R., Pfister S., Omran H. Further evidence for a somatic KRAS mutation in a pilocytic astrocytoma. Neuropediatrics 2007, 38:61-63.
228. Kaul A., Chen Y.H., Emnett R.J., Dahiya S., Gutmann D.H. Pediatric glioma-associated KIAA1549:BRAF expression regulates neuroglial cell growth in a cell type-specific and mTOR-dependent manner. Genes Dev. 2012, 26:2561-2566.
229. Li X., Newbern J.M., Wu Y., et al. MEK is a key regulator of gliogenesis in the developing brain. Neuron 2012, 75:1035-1050.
230. Tabori U., Rienstein S., Dromi Y., et al. Epidermal growth factor receptor gene amplification and expression in disseminated pediatric low-grade gliomas. J. Neurosurg. 2005, 103:357-361.
231. Berman D.M., Karhadkar S.S., Hallahan A.R., et al. Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 2002, 297:1559-1561.
232. Sarangi A., Valadez J.G., Rush S., Abel T.W., Thompson R.C., Cooper M.K. Targeted inhibition of the Hedgehog pathway in established malignant glioma xenografts enhances survival. Oncogene 2009, 28:3468-3476.
233. Rush S.Z., Abel T.W., Valadez J.G., Pearson M., Cooper M.K. Activation of the Hedgehog pathway in pilocytic astrocytomas. Neuro. Oncol. 2010, 12:790-798.
234. Sie M., de Bont E.S., Scherpen F.J., Hoving E.W., den Dunnen W.F. Tumour vasculature and angiogenic profile of paediatric pilocytic astrocytoma; is it much different from glioblastoma?. Neuropathol. Appl. Neurobiol. 2010, 36:636-647.
235. Tatevossian R.G., Tang B., Dalton J., et al. MYB upregulation and genetic aberrations in a subset of pediatric low-grade gliomas. Acta Neuropathol. 2010, 120:731-743.
236. Clappier E.C.W., Kalota A., Crinquette A., Cayuela J.M., Dik W.A., Langerak A.W., Montpellier B., Nadel B., Walrafen P., Delattre O., Aurias A., Leblanc T., Dombret H., Gewirtz A.M., Baruchel A., Sigaux F., Soulier J. The C-MYB locus is involved in chromosomal translocation and genomic duplications in human T-cell acute leukemia (T-ALL), the translocation defining a new T-ALL subtype in very young children. Blood 2007, 110:1251-1261.
237. Lahortiga I., De Keersmaecker K., Van Vlierberghe P., et al. Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nat. Genet. 2007, 39:593-595.
238. Kauraniemi P., Hedenfalk I., Persson K., et al. MYB oncogene amplification in hereditary BRCA1 breast cancer. Cancer Res. 2000, 60:5323-5328.
239. Wallrapp C., M-PF, Solinas-Toldo S., Lichter P., Friess H., Büchler M., Fink T., Adler G., Gress T.M. Characterization of a high copy number amplification at 6q24 in pancreatic cancer identifies c-myb as a candidate oncogene. Cancer Res. 1997, 57:3135-3139.
240. Ramkissoon L.A., Horowitz P.M., Craig J.M., et al. Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:8188-8193.
241. Rodriguez-Paredes M., Esteller M. Cancer epigenetics reaches mainstream oncology. Nat. Med. 2011, 17:330-339.
242. Bird A. Perceptions of epigenetics. Nature 2007, 447:396-398.
243. Costa F.F. Non-coding RNAs, epigenetics and complexity. Gene 2008, 410:9-17.
244. Corn P.G.K.S., van Noesel M.M., Esteller M., Compitello N., Baylin S.B., Herman J.G. Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5' CpG island methylation. Cancer Res. 1999, 59:3352-3356.
245. Kuerbitz S.J., Pahys J., Wilson A., Compitello N., Gray T.A. Hypermethylation of the imprinted NNAT locus occurs frequently in pediatric acute leukemia. Carcinogenesis 2002, 23:559-564.
246. Wagner K.J., Cooper W.N., Grundy R.G., et al. Frequent RASSF1A tumour suppressor gene promoter methylation in Wilms' tumour and colorectal cancer. Oncogene 2002, 21:7277-7282.
247. Choy K.W., Pang C.P., To K.F., Yu C.B., Ng J.S., Lam D.S. Impaired expression and promotor hypermethylation of O6-methylguanine-DNA methyltransferase in retinoblastoma tissues. Invest. Ophthalmol. Vis. Sci. 2002, 43:1344-1349.
248. Wong I.H., Chan J., Wong J., Tam P.K. Ubiquitous aberrant RASSF1A promoter methylation in childhood neoplasia. Clin. Cancer Res. 2004, 10:994-1002.
249. Jones D.T., Jager N., Kool M., et al. Dissecting the genomic complexity underlying medulloblastoma. Nature 2012, 488:100-105.
250. Kieran M.W., Roberts C.W., Chi S.N., et al. Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumors. Pediatr. Blood Cancer 2012, 59:1155-1157.
251. Hasselblatt M., Isken S., Linge A., et al. High-resolution genomic analysis suggests the absence of recurrent genomic alterations other than SMARCB1 aberrations in atypical teratoid/rhabdoid tumors. Genes Chromosomes Cancer 2013, 52:185-190.
252. Schwartzentruber J., Korshunov A., Liu X.Y., et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 2012, 482:226-231.
253. Yu J., Deshmukh H., Gutmann R.J., et al. Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma. Neurology 2009, 73:1526-1531.
254. Melendez B., Fiano C., Ruano Y., Hernandez-Moneo J.L., Mollejo M., Martinez P. BCR gene disruption in a pilomyxoid astrocytoma. Neuropathology 2006, 26:442-446.
255. Hawkins C., Walker E., Mohamed N., et al. BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. Clin. Cancer Res. 2011, 17:4790-4798.
256. Jacob K., Quang-Khuong D.A., Jones D.T., et al. Genetic aberrations leading to MAPK pathway activation mediate oncogene-induced senescence in sporadic pilocytic astrocytomas. Clin. Cancer Res. 2011, 17:4650-4660.
257. Reddy J.P., Li Y. Oncogene-induced senescence and its role in tumor suppression. J. Mammary Gland Biol. Neoplasia 2011, 16:247-256.
258. Horbinski C.N.M., Hagenkord J.M., Hamilton R.L., Pollack I.F. Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas. Neuro. Oncol. 2012, 14:777-789.
259. Dahiya S., Haydon D.H., Alvarado D., Gurnett C.A., Gutmann D.H., Leonard J.R. BRAF(V600E) mutation is a negative prognosticator in pediatric ganglioglioma. Acta Neuropathol. 2013, 125:901-910.
260. Sievert A.J., Lang S.S., Boucher K.L., et al. Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:5957-5962.
261. Poulikakos P.I., Zhang C., Bollag G., Shokat K.M., Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010, 464:427-430.
262. Yalon M., Rood B., MacDonald T.J., et al. A feasibility and efficacy study of rapamycin and erlotinib for recurrent pediatric low-grade glioma (LGG). Pediatr. Blood Cancer 2013, 60:71-76.
263. Krueger D.A., Care M.M., Holland K., et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N. Engl. J. Med. 2010, 363:1801-1811.
264. Franz D.N., Belousova E., Sparagana S., et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013, 381:125-132.
265. Saurez G., Cabanas R., Zaldivar M., et al. Clinical experience with nimotuzumab in Cuban pediatric patients with brain tumors, 2005 to 2007. MEDICC Rev. 2009, 11:27-33.
266. Andre F., Bachelot T., Campone M., et al. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin. Cancer Res. 2013, 19:3693-3702.